Related Experiment Video
Updated: Oct 23, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
Published on: May 17, 2024
Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy
Regan N Theiler1, Myra Wick1, Ramila Mehta2
1From the Division of Obstetrics, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN (Drs Theiler and Wick).
Insights
COVID-19 vaccination during pregnancy is safe and effective, reducing infection rates without increasing complications. Pregnant individuals vaccinated against COVID-19 experienced fewer infections and no adverse outcomes compared to unvaccinated individuals.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Vaccinology
Background:
- SARS-CoV-2 infection in pregnancy poses risks for maternal health and preterm birth.
- COVID-19 vaccines are recommended for pregnant individuals by major medical societies.
- Limited data exist on pregnancy outcomes following COVID-19 vaccination.
Purpose of the Study:
- To evaluate the safety and efficacy of COVID-19 vaccines administered during pregnancy.
- To assess pregnancy and birth outcomes in vaccinated versus unvaccinated pregnant individuals.
Main Methods:
- A delivery cohort was created by integrating a vaccine registry with a healthcare system's delivery database.
- Maternal sociodemographic factors associated with vaccination were analyzed.
- Pregnancy and birth outcomes, including a composite Adverse Outcome Index, were compared between vaccinated and unvaccinated groups.
Main Results:
- 7.0% of 2002 patients received COVID-19 vaccination during pregnancy, with a median gestational age of 32 weeks at first dose.
- Vaccinated pregnant individuals had significantly lower rates of COVID-19 infection before delivery (1.4% vs 11.3%).
- No significant differences were observed in composite adverse outcomes (5.0% vs 4.9%) or other maternal/neonatal complications between vaccinated and unvaccinated groups.
Conclusions:
- COVID-19 vaccination during pregnancy is associated with reduced infection rates.
- Vaccination did not increase the risk of pregnancy or delivery complications in this cohort.
- Findings may not generalize to early pregnancy vaccination due to the cohort's late-vaccination skew.
Background:
SARS-CoV-2 infection during pregnancy is associated with significant maternal morbidity and increased rates of preterm birth. For this reason, COVID-19 vaccination in pregnancy has been endorsed by multiple professional societies, including the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine, despite the exclusion of pregnant women from initial clinical trials of vaccine safety and efficacy. However, to date, little data exist regarding the outcomes of pregnant patients after COVID-19 vaccination.
Objective:
To assess the safety and efficacy of COVID-19 vaccines in pregnant patients.
Study Design:
A comprehensive vaccine registry was combined with a delivery database for an integrated healthcare system to create a delivery cohort that included vaccinated patients. Maternal sociodemographic data were examined to identify factors associated with COVID-19 vaccination. Pregnancy and birth outcomes were analyzed, including a composite measure of maternal and neonatal pregnancy complications, the Adverse Outcome Index.
Results:
Of 2002 patients in the delivery cohort, 140 (7.0%) received a COVID-19 vaccine during pregnancy, and 212 (10.6%) experienced a COVID-19 infection during pregnancy. The median gestational age at first vaccination was 32 weeks (range, 13 6/7-40 4/7 weeks), and patients vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-19 infection before delivery (2/140 [1.4%] vs 210/1862 [11.3%]; P<.001). No maternal COVID-19 infection occurred after the vaccination of pregnant patients. Factors significantly associated with increased likelihood of vaccination in a multivariable logistic regression model included older age, higher level of maternal education, being a nonsmoker, use of infertility treatment for the current pregnancy, and lower gravidity. Compared with unvaccinated patients, no significant difference in the composite adverse outcome (7/140 [5.0%] vs 91/1862 [4.9%]; P=.95) or other maternal or neonatal complications, including thromboembolic events and preterm birth, was observed in vaccinated patients.
Conclusion:
In this birth cohort, vaccinated pregnant women were less likely than unvaccinated pregnant patients to experience COVID-19 infection, and COVID-19 vaccination during pregnancy was not associated with increased pregnancy or delivery complications. The cohort was skewed toward late pregnancy vaccination, and thus, findings may not be generalizable to vaccination during early pregnancy.
Related Concept Videos
Teratogenicity
Vaccinations
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Mitral Valve Prolapse III: Nursing Management

